Next Article in Journal
Neuroprotective Potential of Major Alkaloids from Nelumbo nucifera (Lotus): Mechanisms and Therapeutic Implications
Previous Article in Journal
Determinants for Activation of the Ion Channel TRPV3 by Weak Acids
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome

by
Alexandros Giannakis
1,
Eugenia Kloufetou
1,
Louisa Pechlivani
2,
Chrissa Sioka
2,3,
George Alexiou
2,4,
Spiridon Konitsiotis
1 and
Athanassios P. Kyritsis
1,2,*
1
Department of Neurology, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece
2
Neurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece
3
Department of Nuclear Medicine, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece
4
Department of Neurosurgery, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(17), 8278; https://doi.org/10.3390/ijms26178278
Submission received: 22 July 2025 / Revised: 22 August 2025 / Accepted: 25 August 2025 / Published: 26 August 2025
(This article belongs to the Section Molecular Neurobiology)

Abstract

Although diagnostic criteria and research are constantly advancing, distinguishing between progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) remains a significant challenge. This difficulty stems from their similar clinical symptoms and the lack of reliable biomarkers. In this work, we present a detailed review of fluorodeoxyglucose (FDG)–positron emission tomography (PET), exploring its potential role in differentiating PSP and CBS, drawing on their established utility in other neurodegenerative diseases. We searched the PubMed database from its inception for original research articles assessing the utility of FDG-PET for the diagnosis or differential diagnosis of PSP and CBS from other neurodegenerative conditions. A total of 91 studies were eligible. These 91 studies were categorized as follows: (a) 20 studies included only patients with PSP, (b) 15 studies included only patients with CBS, (c) 39 studies involved patients with Parkinson’s disease and atypical Parkinsonian disorders, including subgroups of PSP and/or CBS, and (d) 17 studies compared patients with PSP and/or CBS to individuals with Alzheimer’s disease, frontotemporal dementia, or other dementias. Most FDG-PET studies involving PSP and CBS were not specifically designed for these disorders. An additional obstacle lies in the methodological variability across studies. Despite several studies achieving high diagnostic accuracy for PSP and/or CBS with specificity exceeding 90% using FDG-PET, sensitivity remains considerably lower. CBS appears to have a distinct hypometabolic pattern compared to PSP, marked by asymmetry and predominant cortical involvement. CBS more often affects posterior cortical regions (parietal and posterior parts of the frontal cortex, and sometimes temporal and occipital parts) and the thalamus, whereas PSP appears to affect the striatum, frontal cortex, anterior cingulate, and subtentorial structures, typically in a more symmetrical manner. Large, multicenter studies are needed, utilizing standardized imaging and protocols.
Keywords: progressive supranuclear palsy; corticobasal syndrome; biomarker; differential diagnosis; positron emission tomography progressive supranuclear palsy; corticobasal syndrome; biomarker; differential diagnosis; positron emission tomography

Share and Cite

MDPI and ACS Style

Giannakis, A.; Kloufetou, E.; Pechlivani, L.; Sioka, C.; Alexiou, G.; Konitsiotis, S.; Kyritsis, A.P. A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome. Int. J. Mol. Sci. 2025, 26, 8278. https://doi.org/10.3390/ijms26178278

AMA Style

Giannakis A, Kloufetou E, Pechlivani L, Sioka C, Alexiou G, Konitsiotis S, Kyritsis AP. A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome. International Journal of Molecular Sciences. 2025; 26(17):8278. https://doi.org/10.3390/ijms26178278

Chicago/Turabian Style

Giannakis, Alexandros, Eugenia Kloufetou, Louisa Pechlivani, Chrissa Sioka, George Alexiou, Spiridon Konitsiotis, and Athanassios P. Kyritsis. 2025. "A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome" International Journal of Molecular Sciences 26, no. 17: 8278. https://doi.org/10.3390/ijms26178278

APA Style

Giannakis, A., Kloufetou, E., Pechlivani, L., Sioka, C., Alexiou, G., Konitsiotis, S., & Kyritsis, A. P. (2025). A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome. International Journal of Molecular Sciences, 26(17), 8278. https://doi.org/10.3390/ijms26178278

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop